Minnesota Senate Bill SF1302

Minnesota 2025-2026 Regular Session

• Introduced: 2/13/25
• Refer: 2/13/25

Caption

Coverage of cancer imaging and clinical genetic testing requirement

Impact

If enacted, SF1302 would have a significant impact on Minnesota's healthcare landscape by altering the scope of insurance coverage regarding cancer-related services. The bill stipulates that certain imaging tests, alongside clinical genetic tests for inherited mutations, must be covered without cost-sharing, which includes exemptions from deductibles and co-payments. This could potentially reduce the financial burden on those diagnosed with or at risk for cancer and encourage more individuals to seek preventive care. Furthermore, it aligns state regulations with national best practices in cancer care.

Summary

Senate File 1302 is a legislative proposal aimed at improving healthcare access for individuals at increased risk of cancer by mandating health insurance plans to provide coverage for specific cancer imaging and clinical genetic testing. This requirement is particularly intended for patients who meet criteria established by the National Comprehensive Cancer Network (NCCN), ensuring they receive necessary screenings without facing financial barriers. The legislation emphasizes the importance of adhering to evidence-based clinical practice guidelines for both imaging and genetic testing.

Contention

There may be points of contention surrounding SF1302, particularly regarding the implications of mandated coverage on health insurance costs and availability. Proponents argue that removing cost-sharing requirements will significantly aid those navigating cancer risks, while critics might raise concerns regarding potential increases in premiums or challenges for insurance providers in implementing these requirements. The balance between providing necessary healthcare coverage and managing the economic impact on insurance markets will likely be a central topic in discussions surrounding the bill.